New pimple patches deliver a powerful remedy to unwanted zits

Waking up with a pimple is no longer cause for panic, thanks to pimple patches — small, sticker-like bandages that cover and help heal the unwanted zit. A team of researchers publishing in ACS Applied Materials & Interfaces has designed a two-stage pimple patch set with an array of tiny spikes that grabs onto the pimple and delivers antibacterial or anti-inflammatory compounds. Human clinical trials confirmed that the pimples completely disappeared after seven days of treatment.

Also called acne stickers, pimple patches are made of polymers that absorb excess moisture and oil. Some versions contain medications that reduce inflammation or fight infection. These medicated stickers often use microarrays (rows of teensy spikes) that penetrate the skin’s outermost layer and deliver compounds underneath. But microarrays may shift during wear and irritate the skin. So, Shayan Fakhraei Lahiji, Yong-Hee Kim and colleagues wanted to design a medicated acne patch system with a microarray platform that stays put.

To create their patch, the researchers first printed a microarray of arrowhead-shaped spikes using a specialized 3D printer. This unique shape helped the patch lock in place when attached to the skin. The patch’s backbone is made of hyaluronic acid — a gooey polymer that’s a common skincare ingredient —that was mixed with either antibacterial agents (including salicylic acid and Cannabis sativa extract) or anti-inflammatory agents (including niacinamide and chamomile extract).    

These patches were clinically tested on 20 participants. On the first day, the participants applied the antibacterial patch, and for the next six days, they applied a new anti-inflammatory patch. The hyaluronic acid-based microarray dissolved into the skin within 30 to 90 minutes, with no pain or irritation. After three days, participants noted an 81% reduction in acne lesions in the treated areas compared to untreated pimples, and after seven days, the treated pimples were gone altogether. Additionally, researchers noted a significant reduction in sebum — an oily substance that causes acne. Around 95% of participants report that they were satisfied with the results of the treatment.

The researchers plan to make their new patch available for purchase in fall 2025, in both South Korea and the United States. In addition, the technology could be reformulated to deliver other therapies, beyond just acne-fighting compounds.

“Our work highlights the potential of microarray patches as a platform for applications beyond acne treatment, ranging from skin disorders to obesity therapies and vaccine delivery,” explains Kim.

The authors acknowledge funding from the Technology Development Program of the Korean Ministry of SMEs and Startups; the Korea Health Technology R&D Project through the Korea Health Industry Development Institute; and the Korean Ministry of Health & Welfare.  

The authors are employees of Cursus Bio Inc., a company focusing on microarray-based technologies. 

###

The American Chemical Society (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.

Registered journalists can subscribe to the ACS journalist news portal on EurekAlert! to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.

Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.

Follow us: Facebook | LinkedIn | Instagram